亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯(lián)系方式|購物車
企業(yè)會員第1年

成都云希化工有限公司  

美容肽,多肽,美容原料,定制肽,醫(yī)藥中間體

搜索
新聞中心
  • 暫無新聞
產(chǎn)品分類
聯(lián)系方式
  • 聯(lián)系人:陳
  • 電話:19150309904
  • 郵件:aileen@youngshechem.com
  • 微信:19150309904
  • QQ:1398029096
站內(nèi)搜索
 
榮譽資質(zhì)
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應(yīng)產(chǎn)品 > Bivalirudin 比伐盧定
Bivalirudin 比伐盧定
單價 10.00 / g對比
銷量 暫無
發(fā)貨 四川成都市付款后3天內(nèi)
庫存 1000g起訂1g
品牌 成都云希
CAS號 128270-60-0
純度 ≥98%
過期 長期有效
更新 2021-07-21 15:06
 
詳細信息

Name:Bivalirudin Trifluoroacetate

Cas No:128270-60-0(net)

Formula: C100H139F3N24O35

Molecular: 2295.31

Sequence: FPRPGGGGNGDFEEIPEEYL

Also known as: CS-1433, HY-15664

Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin. once bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered intravenously. Because it can cause blood stagnation, it is important to monitor changes in hematocrit, activated partial thromboplastin time, international normalized ratio and blood pressure.

 

產(chǎn)品參數(shù):

 

INCI名稱:三***比伐盧定(凝血酶抑制劑)

形狀:白色粉末

PH:無

純度:95%

儲存條件:2~8℃密封避光儲存,長期存儲建議零下15~20℃冷藏最佳

安全性:無重金屬,無皮膚及眼刺激

包裝規(guī)格:1/

注意:本品為科研原料,不建議用于人體

 

©2025 成都云希化工有限公司 版權(quán)所有   技術(shù)支持:化工網(wǎng)   訪問量:41624  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |